AstraZeneca vs Novartis

AstraZeneca (AZN), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novartis is worth $301.5B on the stock market and AstraZeneca $283.9B: Novartis is valued at 6% more. AstraZeneca trades at 25.9 times earnings and Novartis at 30.5; operating margins in their latest fiscal years were 23.4% and 32.4%. Over the past year AstraZeneca's share price has moved +2.75% and Novartis's +25.1%.

Key facts

AstraZeneca market value
$283.9B
Novartis market value
$301.5B
AstraZeneca P/E
25.9
Novartis P/E
30.5
AstraZeneca revenue
$58.7BFY to 2025-12-31
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
7

Market values as of .

AstraZeneca vs Novartis: every measure side by side
Measure AstraZeneca Novartis
SectorHealth CareHealth Care
Country United Kingdom Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$283.9Blower$301.5Bhigher
Revenue$58.7Bhigher$54.5Blower
Earnings$10.2Blower$14Bhigher
Employees96,100higher75,267lower
Total assets$114.1Bhigher$110.9Blower
Valuation
P/E25.9lower30.5higher
P/S4.8lower5.5higher
P/B——
Dividend yield——
Profitability
Operating margin23.4%lower32.4%higher
Balance sheet
Net assets$48.7Bhigher$46.1Blower
Total liabilities$65.4Bhigher$64.4Blower
Total debt$29.6Bhigher$28.7Blower
Cash on hand$5.7Blower$11.4Bhigher
Price change
Today-0.52%lower-0.35%higher
1 year+2.75%lower+25.1%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (7)

AstraZeneca only (5)

Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Novartis). Who owns AZN · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, AstraZeneca or Novartis?

By market value, Novartis is the larger: $301.5B against $283.9B for AstraZeneca. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $54.5B for Novartis.

Which has the higher P/E ratio?

Novartis: 30.5, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Novartis: 32.4%, against 23.4% for AstraZeneca. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

AstraZeneca: $29.6B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AstraZeneca and Novartis?

In their latest 13F filings, Primecap team, Brandon Haley, Larry Robbins, Ken Fisher, Andrew Spokes, Dodge & Cox team and Rajiv Jain hold both.

Cite this page

Funkfolio, “AstraZeneca vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.